Ceramide Remodeling and Risk of Cardiovascular Events and Mortality
BackgroundRecent studies suggest that circulating concentrations of specific ceramide species may be associated with coronary risk and mortality. We sought to determine the relations between the most abundant plasma ceramide species of differing acyl chain lengths and the risk of coronary heart dise...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-05-01
|
| Series: | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
| Subjects: | |
| Online Access: | https://www.ahajournals.org/doi/10.1161/JAHA.117.007931 |
| _version_ | 1811332290346745856 |
|---|---|
| author | Linda R. Peterson Vanessa Xanthakis Meredith S. Duncan Stefan Gross Nele Friedrich Henry Völzke Stephan B. Felix Hui Jiang Rohini Sidhu Matthias Nauck Xuntian Jiang Daniel S. Ory Marcus Dörr Ramachandran S. Vasan Jean E. Schaffer |
| author_facet | Linda R. Peterson Vanessa Xanthakis Meredith S. Duncan Stefan Gross Nele Friedrich Henry Völzke Stephan B. Felix Hui Jiang Rohini Sidhu Matthias Nauck Xuntian Jiang Daniel S. Ory Marcus Dörr Ramachandran S. Vasan Jean E. Schaffer |
| author_sort | Linda R. Peterson |
| collection | DOAJ |
| description | BackgroundRecent studies suggest that circulating concentrations of specific ceramide species may be associated with coronary risk and mortality. We sought to determine the relations between the most abundant plasma ceramide species of differing acyl chain lengths and the risk of coronary heart disease (CHD) and mortality in community‐based samples. Methods and ResultsWe developed a liquid chromatography/mass spectrometry assay to quantify plasma C24:0, C22:0, and C16:0 ceramides and ratios of these very–long‐chain/long‐chain ceramides in 2642 FHS (Framingham Heart Study) participants and in 3134 SHIP (Study of Health in Pomerania) participants. Over a mean follow‐up of 6 years in FHS, there were 88 CHD and 90 heart failure (HF) events and 239 deaths. Over a median follow‐up time in SHIP of 5.75 years for CHD and HF and 8.24 years for mortality, there were 209 CHD and 146 HF events and 377 deaths. In meta‐analysis of the 2 cohorts and adjusting for standard CHD risk factors, C24:0/C16:0 ceramide ratios were inversely associated with incident CHD (hazard ratio per average SD increment, 0.79; 95% confidence interval, 0.71–0.89; P<0.0001) and inversely associated with incident HF (hazard ratio, 0.78; 95% confidence interval, 0.61–1.00; P=0.046). Moreover, the C24:0/C16:0 and C22:0/C16:0 ceramide ratios were inversely associated with all‐cause mortality (C24:0/C16:0: hazard ratio, 0.60; 95% confidence interval, 0.56–0.65; P<0.0001; C22:0/C16:0: hazard ratio, 0.65; 95% confidence interval, 0.60–0.70; P<0.0001). ConclusionsThe ratio of C24:0/C16:0 ceramides in blood may be a valuable new biomarker of CHD risk, HF risk, and all‐cause mortality in the community. |
| first_indexed | 2024-04-13T16:34:35Z |
| format | Article |
| id | doaj.art-d01b8de6f1be44618c9fb0f3db3e2e1c |
| institution | Directory Open Access Journal |
| issn | 2047-9980 |
| language | English |
| last_indexed | 2024-04-13T16:34:35Z |
| publishDate | 2018-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
| spelling | doaj.art-d01b8de6f1be44618c9fb0f3db3e2e1c2022-12-22T02:39:28ZengWileyJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease2047-99802018-05-0171010.1161/JAHA.117.007931Ceramide Remodeling and Risk of Cardiovascular Events and MortalityLinda R. Peterson0Vanessa Xanthakis1Meredith S. Duncan2Stefan Gross3Nele Friedrich4Henry Völzke5Stephan B. Felix6Hui Jiang7Rohini Sidhu8Matthias Nauck9Xuntian Jiang10Daniel S. Ory11Marcus Dörr12Ramachandran S. Vasan13Jean E. Schaffer14Diabetic Cardiovascular Disease Center and Department of Medicine, Washington University, St Louis, MOFramingham Heart Study, Framingham, MAFramingham Heart Study, Framingham, MADepartment of Internal Medicine B, University Medicine Greifswald, Greifswald, GermanyDZHK (German Centre for Cardiovascular Research), partner site, Greifswald, GermanyDZHK (German Centre for Cardiovascular Research), partner site, Greifswald, GermanyDepartment of Internal Medicine B, University Medicine Greifswald, Greifswald, GermanyDiabetic Cardiovascular Disease Center and Department of Medicine, Washington University, St Louis, MODiabetic Cardiovascular Disease Center and Department of Medicine, Washington University, St Louis, MODZHK (German Centre for Cardiovascular Research), partner site, Greifswald, GermanyDiabetic Cardiovascular Disease Center and Department of Medicine, Washington University, St Louis, MODiabetic Cardiovascular Disease Center and Department of Medicine, Washington University, St Louis, MODepartment of Internal Medicine B, University Medicine Greifswald, Greifswald, GermanyFramingham Heart Study, Framingham, MADiabetic Cardiovascular Disease Center and Department of Medicine, Washington University, St Louis, MOBackgroundRecent studies suggest that circulating concentrations of specific ceramide species may be associated with coronary risk and mortality. We sought to determine the relations between the most abundant plasma ceramide species of differing acyl chain lengths and the risk of coronary heart disease (CHD) and mortality in community‐based samples. Methods and ResultsWe developed a liquid chromatography/mass spectrometry assay to quantify plasma C24:0, C22:0, and C16:0 ceramides and ratios of these very–long‐chain/long‐chain ceramides in 2642 FHS (Framingham Heart Study) participants and in 3134 SHIP (Study of Health in Pomerania) participants. Over a mean follow‐up of 6 years in FHS, there were 88 CHD and 90 heart failure (HF) events and 239 deaths. Over a median follow‐up time in SHIP of 5.75 years for CHD and HF and 8.24 years for mortality, there were 209 CHD and 146 HF events and 377 deaths. In meta‐analysis of the 2 cohorts and adjusting for standard CHD risk factors, C24:0/C16:0 ceramide ratios were inversely associated with incident CHD (hazard ratio per average SD increment, 0.79; 95% confidence interval, 0.71–0.89; P<0.0001) and inversely associated with incident HF (hazard ratio, 0.78; 95% confidence interval, 0.61–1.00; P=0.046). Moreover, the C24:0/C16:0 and C22:0/C16:0 ceramide ratios were inversely associated with all‐cause mortality (C24:0/C16:0: hazard ratio, 0.60; 95% confidence interval, 0.56–0.65; P<0.0001; C22:0/C16:0: hazard ratio, 0.65; 95% confidence interval, 0.60–0.70; P<0.0001). ConclusionsThe ratio of C24:0/C16:0 ceramides in blood may be a valuable new biomarker of CHD risk, HF risk, and all‐cause mortality in the community.https://www.ahajournals.org/doi/10.1161/JAHA.117.007931cardiovascular disease risk factorsceramidesmortality |
| spellingShingle | Linda R. Peterson Vanessa Xanthakis Meredith S. Duncan Stefan Gross Nele Friedrich Henry Völzke Stephan B. Felix Hui Jiang Rohini Sidhu Matthias Nauck Xuntian Jiang Daniel S. Ory Marcus Dörr Ramachandran S. Vasan Jean E. Schaffer Ceramide Remodeling and Risk of Cardiovascular Events and Mortality Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease cardiovascular disease risk factors ceramides mortality |
| title | Ceramide Remodeling and Risk of Cardiovascular Events and Mortality |
| title_full | Ceramide Remodeling and Risk of Cardiovascular Events and Mortality |
| title_fullStr | Ceramide Remodeling and Risk of Cardiovascular Events and Mortality |
| title_full_unstemmed | Ceramide Remodeling and Risk of Cardiovascular Events and Mortality |
| title_short | Ceramide Remodeling and Risk of Cardiovascular Events and Mortality |
| title_sort | ceramide remodeling and risk of cardiovascular events and mortality |
| topic | cardiovascular disease risk factors ceramides mortality |
| url | https://www.ahajournals.org/doi/10.1161/JAHA.117.007931 |
| work_keys_str_mv | AT lindarpeterson ceramideremodelingandriskofcardiovasculareventsandmortality AT vanessaxanthakis ceramideremodelingandriskofcardiovasculareventsandmortality AT meredithsduncan ceramideremodelingandriskofcardiovasculareventsandmortality AT stefangross ceramideremodelingandriskofcardiovasculareventsandmortality AT nelefriedrich ceramideremodelingandriskofcardiovasculareventsandmortality AT henryvolzke ceramideremodelingandriskofcardiovasculareventsandmortality AT stephanbfelix ceramideremodelingandriskofcardiovasculareventsandmortality AT huijiang ceramideremodelingandriskofcardiovasculareventsandmortality AT rohinisidhu ceramideremodelingandriskofcardiovasculareventsandmortality AT matthiasnauck ceramideremodelingandriskofcardiovasculareventsandmortality AT xuntianjiang ceramideremodelingandriskofcardiovasculareventsandmortality AT danielsory ceramideremodelingandriskofcardiovasculareventsandmortality AT marcusdorr ceramideremodelingandriskofcardiovasculareventsandmortality AT ramachandransvasan ceramideremodelingandriskofcardiovasculareventsandmortality AT jeaneschaffer ceramideremodelingandriskofcardiovasculareventsandmortality |